2014/1 GaBI Journal Table of Contents

Contents

Editor’s Letter

Editor’s introduction to the initial issue of the third volume of GaBI Journal

Editorial

Drug shortages hit US oncologists hard

Letters to the Editor

Common or distinct INN for biosimilars? Only characteristics of the active substance prior to formulation should be considered

Commentary

Biosimilar monoclonal antibodies approved for use in the EU

The biosimilar name debate: what’s at stake for public health

Original Research

Alternative statistical strategies for biosimilar drug development

Review Article

Statistical considerations for the development of biosimilar products

Perspective

Assuring patient-centred care: engaging patients with rheumatoid arthritis in disease monitoring and pharmacovigilance

Guidelines

New product-specific bioequivalence guidance

Meeting Report

First Asia-Pacific educational workshop on non-biological complex drugs (NBCDs), Kuala Lumpur, Malaysia, 8 October 2013

Special Report

Analysis of European policy towards generic medicines

Regulatory

Comparison of biosimilars guidelines

Abstracted Scientific Content

Biosimilarity of anticancer monoclonal antibodies in the clinic

Sponsored Article

Biosimilar monoclonal antibodies development simplified

Pharma News

Top developments in biosimilars during 2013

Source URL: https://gabi-journal.net/20141-gabi-journal-table-of-contents.html